Mylan Aims To Nix FDA Approval Of Teva's Generic Provigil

Law360, Chicago (April 5, 2012, 3:53 PM EDT) -- Mylan Inc. sued the U.S. Food and Drug Administration on Thursday seeking to derail the marketing exclusivity period the agency awarded Teva Pharmaceuticals USA Inc. for a generic version of Cephalon Inc.'s wakefulness drug Provigil based on patent certifications Mylan says are invalid.

Mylan announced its own offensive in Washington federal court in the generic Provigil battle on the same day that Teva revealed that the FDA decided it was entitled to a 180-day period of market exclusivity because it was the first to file the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.